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Abstract
Background. To cover the shortage of cadaveric
organs, new approaches to expand the donor pool
are needed. Here we report on a case of domino liver
transplantation (DLT) using an organ harvested from
a compound heterozygous patient with primary hyper-
oxaluria (PHO), who underwent combined liver and
kidney transplantation. The DLT recipient developed
early renal failure with oxaluria. The time to the pro-
gression to oxalosis with renal failure in such situa-
tions is unknown, but, based on animal data, we
hypothesize that calcineurin inhibitors may play a
detrimental role.
Methods. A cadaveric liver and kidney transplantation
was performed in a 52-year-old male with PHO. His
liver was used for a 64-year-old patient with a non-
resectable, but limited cholangiocarcinoma.
Results. While the course of the PHO donor was
uneventful, in the DLT recipient early post-operative,
dialysis-dependent renal failure with hyperoxaluria
developed. Histology of a kidney biopsy revealed
massive calcium oxalate crystal deposition as the
leading aetiological cause.
Conclusions. DLT using PHO organs for marginal
recipients represents a possible therapeutic approach
regarding graft function of the liver. However, it
may negatively alter the renal outcome of the recipient
in an unpredictable manner, especially with concomi-
tant use of cyclosporin. Therefore, we suggest that,
although DLT should be promoted, PHO organs are
better excluded from such procedures.
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Introduction
In the domino procedure, the liver harvested from a
patient undergoing a hepatic transplantation to correct
an inherited metabolic disorder is used as a donor
organ for a subsequent graft in a second liver recipient.
Thus, it allows the shortage of cadaveric organs to
be overcome and expands the donor pool. Organs
with a single protein dysfunction, but normal tissue
anatomy, may be acceptable for patients with advanced
hepatic malignancies or for aged recipients. Until
now, this approach has been successfully performed
in several cases of familial amyloid polyneuropathy
(FAP) [1].
Primary hyperoxaluria (PHO) is a rare autosomal
recessive disorder with a variable phenotype. The liver-
speciﬁc deﬁciency of alanine-glyoxylate aminotransfer-
ase (AGT) results in hepatic overproduction of oxalate,
systemic calcium oxalate deposits in bone, heart, vessels
and nerves, hyperoxaluria and end-stage renal disease
after years to decades [2].
Here we report on a patient with a locally advanced
cholangiocarcinoma, who underwent domino liver
transplantation (DLT) using the liver from an adult
donor with compound heterozygous PHO who
subsequently developed renal failure with massive
renal calcium oxalate deposits within a few days after
surgery.
Case
Donor history
A 52-year-old man with dialysis-dependent end-stage
renal disease (ESRD) and normal hepatic function was
selected as a candidate for kidney transplantation.
Of note in his medical history were several episodes
of calcium oxalate nephrolithiasis with repeated
extracorporal shock wave lithothripsy treatments in
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the past 12 years and recurrent urinary tract infections.
In order to obtain a better control of the infectious
complications and in the presence of residual stones
in the renal pelvis, the left kidney was removed at the
age of 49 years. Despite the lower incidence of urinary
tract infections after nephrectomy, renal function
progressively worsened and chronic haemodialysis
was started in the same year. Nine months later, a
ﬁrst kidney transplantation (cadaver graft, 1 DRmatch,
immunosuppression with cyclosporin A, steroids and
MMF) was performed, complicated by primary
delayed graft function and systemic cytomegalovirus
infection. Only 3 months later, the transplanted kidney
was removed because of graft failure, and chronic inter-
mittent haemodialysis treatment was re-established.
Histopathological analysis of the explanted graft
showed diffuse deposition of oxalate crystals in the
renal parenchyma. Additional careful histological
reassessment of the left kidney, which had been
removed 3 years earlier, also showed multiple calcium
oxalate depositions.
The clinical suspicion of PHO was proved by genetic
analysis, demonstrating the loss-of-function G508A
mutation. This mutation represents one of >30 known
mutations [2] of the AGXT gene (encoding AGT)
and accounts for 25% of the mutant alleles in
PHO type I patients. The other mutant allele was not
speciﬁed (compound heterozygous mutation).
Twenty-eight months later, as a suitable cadaveric
donor became available, the patient underwent a com-
bined liver/kidney transplantation. Hepatic work-up
prior to transplantation included liver tests, viral sero-
logy, magnetic resonance imaging (MRI) and duplex
sonography. In the absence of any structural and
functional deﬁciency other than the compound hetero-
zygous PHO mutation and because of the long latency
period until development of ESRD, we considered
using his liver for DLT in a compatible patient with
a non-resectable but limited cholangiocarcinoma. The
donor gave his written consent prior to transplantation
for this procedure. Modiﬁed hepatectomy followed
by standard orthotopic liver transplantation and
renal transplantation in the right iliac fossa was
performed in the PHO patient. At a follow-up of
5 months, the post-transplantation course of the
domino donor was uneventful, with good function of
the liver and kidney graft although marked oxaluria
was present.
Domino recipient history
A 64-year-old man was suffering from a locally
advanced, recurrent (segments IV/VIII) and presently
not resectable cholangiocarcinoma. Two years earlier,
at initial diagnosis, he underwent bisegmental (II/III)
hepatic resection followed by an adjuvant gemcitabine,
then an oxaliplatin/ﬂuorouracil/leucovorin regimen.
Since prognosis with this type of neoplasm is poor
and conventional liver transplantation in this setting
confers a high risk of recurrence and is not a standard
listing criterion, the patient was informed about
the possibility of DLT and gave his written consent
for such a procedure. Tumour assessment prior to
transplantation included liver tests, MRI, colono-
and gastroscopy and chest X-ray. As a co-morbid
condition, the patient presented with a mild renal
insufﬁciency (creatinine clearance 63ml/min) without
proteinuria or haematuria, and the kidney appeared
normal on ultrasound and nuclear magnetic resonance
evaluation. Thus, in the absence of other nephrotoxic
conditions, the mild renal insufﬁciency [glomerular
ﬁltration rate (GFR) 63ml/min] was interpreted as a
consequence of now controlled, yet long-standing
arterial hypertension. Consequently, no further evalua-
tions such as renal biopsy were performed prior
to transplantation, and a diagnosis of suspected
nephroangiosclerosis was given.
Orthotopic hepatic transplantation into the domino
recipient was performed without any technical pro-
blems, the cold ischaemia time was 4 h and 40min. The
initial immunosuppressive therapy consisted of high
dose steroids and cyclosporin A (Figure 1). The post-
operative course was uneventful for wound healing and
hepatic function, but was complicated by a rapid
decline of renal function (Figure 1). Concurrently, we
noted a marked increase of oxaluria (Figure 1) and
a rapidly progressive sonographic hyperechogenicity
of the renal parenchyma, suggestive of renal oxalate
deposition. All possible causes of a secondary hyper-
oxaluria were excluded (diarrhoea, increased dietary
oxalate intake). Despite early hyperhydratation and
administration of alkaline agents, thiazide diuretics
and high-dose pyridoxine (a cofactor of AGT),
further renal oxalate deposition could not
be prevented, as shown by a renal biopsy 18 days
after transplantation. Progression to dialysis-
dependent organ failure occurred within 12 days
post-operatively. At a follow-up of 4 months and in
the presence of a newly developed chest wall meta-
stasis, the patient was switched from cyclosporin A
to sirolimus and a palliative treatment with gemcitabine
was started. Despite calcineurin inhibitor-free
immunosuppression, renal function did not recover
and the patient remained on chronic, ambulant
haemodialysis with normal liver function. He died
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Fig. 1. Creatinine (mmol/l, normal range 59–104), urine oxalate
excretion (mmol/l/mmol creatinine, normal range 15–32) and
cyclosporin A trough levels (ng/ml) in the domino recipient.
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8 months after transplantation from a bacterial
pneumonia.
Discussion
DLT represents one of several ways to overcome
the shortage of cadaveric organs and expands the
donor pool in particular circumstances. The purpose
of such a procedure is to harvest an organ with a single
protein defect for a marginal recipient with compro-
mised long-term prognosis. Therefore, the natural
course of the ‘transplanted disease’ should be longer
than the expected post-transplant survival. Performing
a DLT does not create an additional risk for the
domino donor [1]. The principal technical issue in DLT
is the sectioning of the suprahepatic vena cava, and so
providing an adequate cuff for both the donor and
the explanted liver. In the literature, most cases of
DLT are described using organs from patients with
FAP [1]. In FAP, the structure of transthyretin, a
liver-derived plasma protein, is abnormal and its accu-
mulation causes symptomatic disease after a latency
of 30–40 years.
In our case, the liver of a compound heterozygous
PHO patient was used. PHO is a rare autosomal
recessive disease that results from endogenous over-
production of oxalic acid, as opposed to secondary
hyperoxaluria, which is induced by increased intestinal
absorption or excessive dietary intake of oxalate.
In type I PHO, which represents the most common
form, the activity of the liver-speciﬁc peroxisomal
enzyme AGT is low or absent. One-half of the patients
show no detectable AGT activity, whereas the other
half have variable enzyme activity ranging from 2
to 48% [2,3]. Interestingly, even patients with residual
activity may not differ phenotypically from those
without activity, a fact that has been attributed to a
mistargeting of the enzyme to the mitochondria
instead of the peroxisomes [2,3]. As a consequence of
the altered AGT activity, urinary excretion of oxalate
and, in most cases of type I PHO, also glycolate
is increased. Since oxalate is freely ﬁltered at the
glomerular level, it is present at high concentrations in
the proximal tubule, where it can act as a predis-
posing factor for urinary stone formation. Apart from
deposition of calcium oxalate crystals in the renal
parenchyma, and thereby induction of a foreign body
reaction, high oxalate concentrations in the tubular
ﬂuid have direct toxic effects on tubular cells, probably
by promoting the production of free radicals [4].
This mechanism may directly contribute to the rapid
deterioration of renal function observed in PHO
patients in contrast to the slower decline in renal
function associated with nephrocalcinosis of other
origins.
Currently we found only two published cases in the
literature reporting a DLT harvesting PHO organs
[5,6]. In one case, a split graft was used in a neonate
with fulminant hepatic failure as a bridge to deﬁnitive
liver transplantation within 4 months. The authors
report early, but transient deterioration of renal
function and signs of early nephrocalcinosis in a CT
scan 3 months after DLT. The other case reports a
69-year-old male with hepatitis C-related cirrhosis and
a multifocal hepatocellular carcinoma who received
the liver of a PHO donor. Recovery was uneventful,
but hyperoxaluria was observed and renal function
worsened from a creatinine clearance of 95ml/min
(pre-operative) to 43ml/min at a follow-up of 8 months.
In both cases, a cyclosporin-containing immunosup-
pressive regimen was used. In a third, unpublished case
(Dr G. Mentha, Geneva, Switzerland, personal com-
munication), the DLT recipient has a good liver
function at a follow-up of 5 years without relapse of
the initial hepatocellular carcinoma, but also develo-
ped dialysis-dependent ESRD. In our case, dialysis-
dependent renal failure of the native kidneys developed
12 days after transplantation and was histologically
proved to be associated with massive deposits of
calcium oxalate crystals in the renal parenchyma.
Supersaturation of the plasma with calcium oxalate
and subsequent systemic oxalate deposition occur
earlier in the course of renal insufﬁciency in PHO
patients compared with non-PHO patients with hyper-
oxaluria and renal failure. Calcium oxalate saturation
increases markedly at a GFR of <45 and <8ml/min,
respectively, in these patients [2]. Since our recipient
had a GFR well above these limits, mobilization of
pre-existing systemic oxalate deposits after transplan-
tation seems to be less probable as an explanation
for the deleterious course. When the transplantation of
a PHO organ to a non-PHO patient causes a suddenly
released oxalate load that is high enough to cause rapid
renal failure, and when this problem is preventable
by forced ﬂuid intake is not known to us. The only
comparable published case is cited above [6], where
renal function declined over a much longer period.
In the presence of a previously stable kidney function
over decades in the compound heterozygous PHO
donor, one could speculate about a possible (enhanced)
toxicity of the cyclosporin-containing immunosuppres-
sive regimen as a reason for the rapid decline in the
renal function of our DLT recipient. Since it is well
known that calcineurin inhibitors can negatively alter
GFR, the rapid oxalate deposition in the kidney may
be explained by a reduced GFR in the presence of the
additional transplanted ‘oxalate load’. Additionally,
there is evidence that calcineurin inhibitors may
induce renal tubular acidosis, another lithogenic
condition associated with hypocitraturia and calcinosis
of the renal parenchyma. On the other hand, Selvam
and Adhirai demonstrated in a rat model that
cyclosporin per se induced hyperoxaluria, and admin-
istration of the drug to hyperoxalic rats potentiated
the deposition of calcium oxalate crystals by different
mechanisms in renal parenchyma. First, damaged cell
membranes enhanced the nucleation of calcium oxalate
crystals at a lower supersaturation, and secondly,
cyclosporin treatment in these animals resulted in
stimulating production of calcium oxalate-binding
proteins that can act as a nucleus for crystallization.
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Of note, renal and liver tissues of the cyclosporin-
treated hyperoxaluric animals were depleted of
antioxidants such as reduced glutathione, vitamin E
and C, and showed increased lipid peroxidation from
membrane damage of the cells. In these experiments,
the excessive, cyclosporin-induced crystal deposition
was prevented by administration of the antioxidant
vitamin E [7–9], suggesting an oxidative stress-related
mechanism.
Patients with PHO undergoing kidney transplanta-
tion alone for ESRD have been shown to have impaired
graft survival compared with control groups [2,10].
To our knowledge, it is not known if calcineurin
inhibitors, by inducing hyperoxaluria or promoting
intrarenal nucleation of calcium oxalate, may contri-
bute to the impaired outcome after renal transplanta-
tion in this population. Since hyperoxaluria per se
promotes the formation of free radicals, we hypothesize
that the combination with an antioxidant-depleting
calcineurin inhibitor in our DLT recipient could have
played a role in the rapid progression of renal failure.
Whether our PHO donor lost his ﬁrst renal graft
by a cyclosporin-induced mechanism, by mobilization
of the systemic oxalate deposits after transplantation or
both is not clear.
As a conclusion, based on our case report and the
limited published data, we suggest that PHO organs
should not be used for DLT. The heterogeneity of
the disease, the poor correlation between severity
and biochemical parameters as well as the increasing
number of known AGXT gene mutations (whose
signiﬁcance is not clearly understood) may produce
an unpredictable course after transplantation and
immunosuppression, even when organs from com-
pound heterozygous donors with a long latency
period to symptomatic disease are used. In this setting,
calcineurin inhibitors, apart from their well known
vasoconstriction-mediated nephrotoxicity, may play
a speciﬁc role in increasing intrarenal calcium oxalate
deposition and thereby damaging the kidneys.
Finally, PHO in our DLT donor was diagnosed
only after a ﬁrst unsuccessful renal transplantation.
Therefore, nephrologists and urologists treating young
adults with nephrolithiasis should remain vigilant in
order to not overlook PHO and prevent a delay in
diagnosis of the disease.
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